Tolvaptan for treatment of iatrogenic hyponatremia

CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2016; 03(01): 060-061
DOI: 10.4103/2348-0548.173242

Correspondence

Thieme Medical and Scientific Publishers Private Ltd.

Dhaval Shukla

¹Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India

REFERENCES
1 Lee JJ, Kilonzo K, Nistico A, Yeates K. Management of hyponatremia. CMAJ 2014; 186: E281-6
2 Verbalis JG, Grossman A, Höybye C, Runkle I. Review and analysis of differing regulatory indications and expert panel guidelines for the treatment of hyponatremia. Curr Med Res Opin 2014; 30: 1201-7
3 Rangarajan B, Binoy V, Hingmire SS, Noronha V. Tolvaptan. South Asian J Cancer 2014; 3: 182-4
4 Ooi HL, Maguire AM, Ambler GR. Desmopressin administration in children with central diabetes insipidus: A retrospective review. J Pediatr Endocrinol Metab 2013; 26: 1047-52
5 Lucchini B, Simonetti GD, Ceschi A, Lava SA, Faré PB, Bianchetti MG. Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: A systematic review. J Pediatr Urol 2013; 9 (6 Pt B) 1049-53